230 related articles for article (PubMed ID: 16091194)
1. Immunotherapy for acute myeloid leukemia.
Jurcic JG
Curr Oncol Rep; 2005 Sep; 7(5):339-46. PubMed ID: 16091194
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based treatment of acute myeloid leukaemia.
Mulford DA; Jurcic JG
Expert Opin Biol Ther; 2004 Jan; 4(1):95-105. PubMed ID: 14680472
[TBL] [Abstract][Full Text] [Related]
3. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
Jurcic JG
Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
[TBL] [Abstract][Full Text] [Related]
4. Antibody therapy in acute myeloid leukemia: current status and future directions.
Burke JM; Jurcic JG
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S12-8. PubMed ID: 11970765
[TBL] [Abstract][Full Text] [Related]
5. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
7. Antibody therapy of acute myelogenous leukemia.
Jurcic JG
Cancer Biother Radiopharm; 2000 Aug; 15(4):319-26. PubMed ID: 11041016
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects.
Leone G; Sica S; Voso MT; Rutella S; Pagano L
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):33-52. PubMed ID: 16529548
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
12. What happened to anti-CD33 therapy for acute myeloid leukemia?
Jurcic JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
14. Antibody therapy for residual disease in acute myelogenous leukemia.
Jurcic JG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):37-45. PubMed ID: 11255080
[TBL] [Abstract][Full Text] [Related]
15. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific immunotherapies for acute myeloid leukemia.
Buckley SA; Walter RB
Hematology Am Soc Hematol Educ Program; 2015; 2015():584-95. PubMed ID: 26637776
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
19. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
20. [Antibody directed therapy for leukemia].
Takeshita A; Naito K; Ohno R
Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]